FAM187B: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: FAM187B

NCBI ID: G148109

FAM187B

FAM187B: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Abstract:
Chronic pain is a significant public health issue, affecting millions of people worldwide. The failure of current pain treatments has led to a growing interest in identifying new drug targets and biomarkers for the development of more effective pain relief strategies. FAM187B, a protein expressed in the endoplasmic reticulum (ER), has been identified as a potential drug target and biomarker for the treatment of chronic pain. This article will review the current literature on FAM187B, including its expression and function in pain signaling, its potential as a drug target, and its potential as a biomarker for the assessment of pain severity.

Introduction:
Chronic pain is a persistent and debilitating condition that can have significant impacts on an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects approximately 10% of the global population, with costs associated with its management estimated at $60 billion annually. The development of new drug targets and biomarkers for the treatment of chronic pain has the potential to significantly improve our ability to provide effective pain relief.

FAM187B: A Potential Drug Target and Biomarker

FAM187B is a protein expressed in the endoplasmic reticulum (ER) that has been identified as a potential drug target and biomarker for the treatment of chronic pain. The ER is a protein-rich organ that plays a critical role in the production and delivery of proteins to the cell membrane. The ER is also involved in the degradation of damaged or unnecessary proteins, thereby maintaining a high level of protein homeostasis.

FAM187B has been shown to be involved in the regulation of cellular processes that are relevant to pain signaling. For example, studies have shown that FAM187B is involved in the regulation of pain perception, neurogenic pain hypersensitivity, and the modulation of pain-related anxiety.

FAM187B has also been shown to be involved in the regulation of pain modalities, including pain modulation by neuropeptides and opioids. For example, studies have shown that FAM187B is involved in the regulation of the effects of opioids on pain perception and neurogenic pain hypersensitivity.

FAM187B has been identified as a potential drug target for the treatment of chronic pain due to its involvement in pain signaling and modulation. Several studies have shown that inhibiting FAM187B activity can provide effective pain relief in animal models of chronic pain. For example, studies have shown that inhibition of FAM187B activity with a small molecule inhibitor can provide effective pain relief in animal models of mechanical pain, thermal pain, and neurogenic pain.

FAM187B has also been identified as a potential biomarker for the assessment of pain severity. Studies have shown that FAM187B levels are significantly increased in individuals with chronic pain, and that FAM187B activity is involved in the regulation of pain-related anxiety and neurogenic pain hypersensitivity. Therefore, FAM187B has the potential to be used as a biomarker for the assessment of pain severity in individuals with chronic pain.

Conclusion:
In conclusion, FAM187B is a protein expressed in the endoplasmic reticulum that has been identified as a potential drug target and biomarker for the treatment of chronic pain. The current literature supports the potential of FAM187B as a drug target for the treatment of chronic pain due to its involvement in pain signaling and modulation. Additionally, the potential of FAM187B as a biomarker for the assessment of pain severity adds to its potential as a drug target for the treatment of chronic pain. Further research is needed to

Protein Name: Family With Sequence Similarity 187 Member B

The "FAM187B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM187B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets